Skip to main content

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment

Written by Customer Service on . Posted in Public Companies.

MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma.1

Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Aires, Argentina), the study provides the first quantitative computer model comparing the thermal tissue effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser therapy using MicroPulse® technology (MicroPulse TLT) with Iridex’s Cyclo G6® Laser, G-Probe® and MicroPulse P3® delivery devices.

Using advanced Monte Carlo computer simulations, the authors modeled how each technique heats the ciliary body and quantified temperature peaks, duration, and thermal spread. The modeling revealed that CW TSCPC produced a 2 mm-wide zone of tissue heating with temperatures exceeding 100°C for approximately 2.2 seconds. MicroPulse TLT generated a smaller 0.6-1.2 mm thermal zone and shorter duration peak temperatures, remaining below 100°C. Additionally, MicroPulse TLT showed a more uniform heat distribution than CW-TSCPC.

Dr. Grippo explained, “Our study uses a computational model to analyze heat behavior in the ciliary body during CW-TSCPC and MicroPulse TLT treatments. By linking these findings to the safety, effectiveness, and mechanisms of action described in the literature for both treatments, we can reinterpret existing clinical evidence from a fresh perspective. This approach strengthens our understanding and conceptual framework for these techniques and provides insights that may help refine both laser procedures for improved patient outcomes.”

The authors concluded that both techniques share a thermal continuum, and with further optimization, each may evolve to serve distinct but complementary roles from refractory glaucoma to earlier intervention cases.

“Dr. Grippo’s work underscores Iridex’s commitment to advancing evidence-based innovation in glaucoma care,” said Patrick Mercer, CEO of Iridex Corporation. “By deepening our scientific understanding of how these two transscleral laser approaches interact with ocular tissues, we can continue to improve treatment optimization and safety creating broad clinical opportunities for both CW-TSCPC and MicroPulse TLT in modern glaucoma management.”

The article is available in Translational Vision Science & Technology.

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com

Media Contact
Joan Stauffer
jstauffer@iridex.com

For more information about Iridex technologies, visit www.iridex.com.

Iridex, the Iridex logo, MicroPulse®, the MicroPulse logo, Cyclo G6, MicroPulse P3®, and G-Probe® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.

References

  1. Grippo TM, LaMarche K, Davreux AM, Stauffer J, Stacey S, Arnold K. Thermal tissue modeling of the ciliary body with continuous wave transscleral cyclophotocoagulation and transscleral laser therapy using micropulse technology. Transl Vis Sci Technol. 2025;14(11):32.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.